WHO ICTRP trial
Pirfenidone for COVID-19 related lung fibrosis
CTRI/2021/03/032199 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2021/03/032199 |
|---|---|
| Public title | Pirfenidone for COVID-19 related lung fibrosis |
| Scientific title | Pirfenidone for coronavirus disease 2019 (COVID-19) related pulmonary fibrosis: A placebo-controlled randomized controlled trial |
| Primary sponsor | Anant Mohan |
| Secondary sponsors | Ashu Seith Bhalla;Karan Madan;Pawan Tiwari;Priyanka Naranje;Randeep Guleria;Ravindra Mohan Pandey;Saurabh Mittal;Vijay Hadda |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 3 |
| Countries | India |
| Conditions | Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere |
| Interventions | Intervention1: Pirfenidone tablet 800 mg three times a day: For 6 months Control Intervention1: Matched Placebo 800 mg for three times per day: For 6 months |
| Registration date | Mar 22, 2021 |
| Target size | 60 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: